双重动脉药物灌注治疗中晚期非小细胞型肺癌（附10例报告）

TREATMENT OF NON-SMALL-CELL LUNG CANCER BY DUAL(BRONCHIAL AND PULMONARY)ARTERIAL DRUG INFUSION

经选择性支气管动脉灌注（ＢＡＩ）和经肺动脉药物灌注（ＰＡＩ）治疗中晚期非小细胞型肺癌１０例，共４２例次，近期有效率达８０％，使５例获得手术治疗机会。全组中位生存期１１．５个月。作者对双重动脉药物灌注的机理，疗效进行了分析，指出ＤＡＩ可以使高浓度化疗药物充分与肺肿瘤细胞接触，发挥最佳疗效。对ＢＡＩ插管困难或支气管动脉无优势供血的肺肿瘤，可经ＰＡＩ增强疗效，ＤＡＩ治疗减少了ＢＡＩ的次数并可减少由ＢＡＩ引起的并发症。

AbstractSince the lung receives blood supply from both the bronchial and pulmonary arteries,chemotherapeutic agents given through both channels would give higher local drug concentra-tion and better therapeutic results in the treatment of lung cancer.In this study,10 patientswith advanced NSCLC were treated by dual arterial infusion(DAI)of carboplatin(300mg/m￣2)and VP-16(200～300mg/m￣2)twice at 3-week interval.From DAI treatment,a response rate of 80%(CR 2, PR 6)was achieved.In 5 patients DAI treatment had madesurgical resection of the lung cancer possible. The 1-,2-and 3-year survivors were 8,6 and5 respectively,with a median survival time of 11.5 months.